US FDA’s final guidance spells out how to use standard dissolution methods for new drug applications and abbreviated new drug applications for highly soluble immediate-release solid oral dosage forms. FDA said that the guidance should also facilitate the agency’s review of the data submitted in applications.
The guidance also describes when a standard release test may be used in lieu of extensive method development and acceptance...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?